isnobs & comparison to dexcom

I have done a bit of research on Dexcom (Nasdaq: DXCM) which has a market cap of $1.2 billion. Although annual sales are approaching $ 100 million, they are yet to return a profit.
http://www.dlife.com/diabetes/blood_sugar_management/testing/kelly_close/g4_platinum?page=1
Note on p.3 that most users are awaiting release of DEXCOM's new GEN5 which will "automatically upload CGM data to the clod & remote monitoring".Sounds familiar !
I find it mindboggling that U.S. investors value the company at $1.2B without returning a profit.

The Directors seem to be on top of things and will hopefully not fall into the same mistakes as other mHealth and digital monitoring companies.

As ISN price moves higher I believe we will start to see U.S. investors getting involved. Launch of Airsonea in Australia in Sep 2013 will add additional momentum with the BIG move coming as we approach Jan 2014 and FDA approval. This is completely any potential agreements with the likes of CVS etc.

With approx 220 million shares on issue if everything goes to plan, the ISN share price could be well above $1 within 12 months.

The oppies (ISNOB) with a exerc price of 14 cents & exp date of 30 June 2014 are well worth a look at. I was surprised to see that there are only 20.75 million on issue. Here are some examples of potential returns:
(based on price of 3cents)
Ords 15c OBs 6 Ret 100%
Ords 20c OBs 9 Ret 200%
Ords 25c OBs 13 Ret 333%
Ords 50c OBs 36 Ret 1,200%